SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?

Ahmed-Sarwar, Nabila; Nagel, Angela; Leistman, Samantha; Heacock, Kevin

doi:10.1177/1060028017710481

Cited by 17 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By inhibiting reabsorption of filtered glucose in the proximal tubule to increase urinary glucose excretion, SGLT2 inhibitors lower blood glucose levels independently of insulin [4]. Therefore, when used alongside insulin, SGLT2 inhibitors offer a means of improving glycaemic control without increasing the risk of insulin-related adverse effects [8]. As SGLT2 inhibitors may improve CV outcomes and bodyweight [9, 10], they may be of particular benefit to patients with high body mass indices (BMI).…”

Section: Introductionmentioning

confidence: 99%

Dapagliflozin: A Review in Type 1 Diabetes

Paik

Blair

2019

Drugs

View full text Add to dashboard Cite

Oral dapagliflozin (Edistride ® , Forxiga ®) is approved in the EU at a dosage of 5 mg/day as an adjunct to insulin in adults with type 1 diabetes (T1D) and a body mass index (BMI) of ≥ 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. As a highly selective SGLT2 inhibitor, dapagliflozin decreases plasma glucose levels independently of insulin action and enables glycaemic control improvement without increasing the risks associated with intensive insulin therapy. In the phase III DEPICT-1 and-2 trials, dapagliflozin 5 mg/day as an adjunct to insulin improved glycaemic control and reduced total daily insulin dose and bodyweight relative to placebo in adults with inadequately controlled T1D, including in patients with a BMI of ≥ 27 kg/m 2 , over 24 weeks of treatment. In extensions of these trials, these improvements were maintained up to 52 weeks. Dapagliflozin was generally well tolerated with a manageable safety profile and a hypoglycaemia profile generally similar to placebo. The incidence of diabetic ketoacidosis with dapagliflozin in patients with a BMI ≥ 27 kg/m 2 was less than half that of the overall population who received dapagliflozin. Dapagliflozin is the first SGLT2 inhibitor to be approved for use in T1D and, while further clinical experience in T1D is required to more definitively establish its efficacy and safety profile, it provides a promising adjunctive treatment option for adults with T1D and a BMI of ≥ 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Dapagliflozin: A Review in Type 1 Diabetes

Paik

Blair

2019

Drugs

View full text Add to dashboard Cite

show abstract

“…8 Thus, SGLT2 inhibitors alongside insulin may provide a new way, promoting glycaemic control without the increased risk of insulin-related adverse effects. 18 In T2DM patients, SGLT2 inhibitors could lower HbA1c, blood pressure and body weight without increasing major hypoglycaemic events through a non-pancreatic-dependent mechanism of action. 19 Dapagliflozin, an SGLT2 inhibitor, was the first oral treatment approved in T1DM in the European Union, indicating as an adjunct to insulin in adults with T1DM whose BMI of ≥27 kg/m 2 , when insulin alone did not provide adequate glycaemic control despite optimal insulin therapy.…”

Section: Discussionmentioning

confidence: 99%

Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients

Wang

Han

et al. 2021

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objectives: Dapagliflozin was the first oral treatment approved in type 1 diabetes mellitus (T1DM) patients, simultaneously improving body weight.However, the time course and dose effect of dapagliflozin on loss of weight in T1DM patients was still unknown. The present study aimed to investigate quantitative relationship between dapagliflozin and loss of weight in T1DM patients based on Modelbased Meta-analysis.Methods: Five dapagliflozin dosage groups, two of them were 5 mg/day and three of them were 10 mg/day, 1612 T1DM patients were analysed with maximal effect (E max ) model, and evaluation index was change rate of body weight from baseline value.

show abstract

“…However, CGM use and data interpretation requires training and experience, has had slow adoption, and its potential remains to be fully realized. Likewise, use of therapies currently approved for the treatment of type 2 diabetes have improved outcomes in T1D such as body weight and insulin dose reductions, insulin sensitization, lowering HbA1c, increasing time in desired glucose range and even reducing glycemic variability; however, most studies have shown responses span the gamut from nonresponders to super-responders [135][136][137][138][139] , thus emphasizing the need for strat-ified, precision medicine approaches. The novel class of SGLT inhibitors, both mono SGLT2 and dual SGLT1/2, are currently in pivotal T1D label expansion studies by manufacturers.…”

Section: Early Stage 3 T1dmentioning

confidence: 99%

Type 1 Diabetes: Disease Stratification

Insel¹,

Dutta²,

Hedrick³

2017

Biomed Hub

View full text Add to dashboard Cite

Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease.

show abstract

SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?

Cited by 17 publications

References 21 publications

Dapagliflozin: A Review in Type 1 Diabetes

Dapagliflozin: A Review in Type 1 Diabetes

Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients

Type 1 Diabetes: Disease Stratification

Contact Info

Product

Resources

About